Rinvoq provides treatment for adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers.
The Food and Drug Administration has given Alembic clearance for formoterol fumarate inhalation solution and tentative approval for selexipag tablets in various dosage strengths.
Alembic's generic Bactroban provides a treatment for secondarily infected traumatic skin lesions due to susceptible isolates of Staphylococcus aureus and Streptococcus pyogenes.
Eagle Pharmaceuticals received 180 days of marketing exclusivity from the Food and Drug Administration for its recently approved generic version of Endo’s Vasostrict (vasopressin).
Novartis has obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals.